BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Volkswagen in talks with defence firms on use of Germany plant: CEO - 2More parents refusing this shot that prevents serious bleeding at birth
- 3See as Your #1: These Low-Sugar Food sources You Ought to Attempt
- 4NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- 5Exclusive-Head of Pemex's production arm to step down in coming days, sources say
- Wedding trip Objections in Europe
- Sentimental tree to shine at Arctic League annual broadcast
- Israeli archaeologists launch project to trace origins of ancient pottery
- Syrian army says recent drone attacks targeted its bases near Iraq, most shot down
- Vote In favor of Your Favored Web-based Book Retailor
- Massive supernova explosion may have created a binary black hole
- Instructions to Distinguish the Wellbeing Dangers Related with 5G Pinnacles
- 12 times rockets and spacecraft crashed and burned in 2025
- A definitive Manual for the 5 Off-road Bicycles Available
